• Axsome Therapeutics recently highlighted the upcoming release of its first-quarter 2026 results on May 4 and the pending US Food and Drug Administration decision on Auvelity for agitation associated with Alzheimer's disease, a potential new indication for its central nervous system portfolio.
• Analysts see the Alzheimer's agitation application for Auvelity as a potentially meaningful new revenue stream, given the high unmet medical need and expectations that the drug may avoid an added mortality boxed warning due to its existing antidepressant classification.
• We will now examine how the anticipated FDA decision on Auvelity for Alzheimer’s agitation could influence Axsome’s broader investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.

Axsome Therapeutics Investment Narrative Recap

To own Axsome Therapeutics, you need to believe its focused central nervous system portfolio can eventually scale into a profitable, multi-product franchise despite current net losses and heavy spending. The upcoming FDA ruling on Auvelity in Alzheimer’s agitation is the key near term catalyst, while execution risk around high SG&A and pricing pressure on Auvelity, Sunosi and SYMBRAVO remains a central concern. The latest Auvelity news reinforces that concentration risk rather than changing it.

The most relevant recent announcement here is the scheduled first quarter 2026 results and business update on May 4. That call should give investors fresh detail on Auvelity’s current uptake, gross to net dynamics and commercialization costs, which matter directly for assessing how impactful an Alzheimer’s agitation indication might be to Axsome’s revenue mix, cash burn and reliance on a small set of core products.

However, against this potential upside, investors should also be aware of rising SG&A and the possibility that...

Axsome Therapeutics' narrative projects $2.1 billion revenue and $744.1 million earnings by 2029.

Uncover how Axsome Therapeutics' forecasts yield a $223.66 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling Axsome revenue of about US$2.5 billion and US$1.4 billion in earnings by 2028, which assumes smooth regulatory progress on AXS 05 in Alzheimer’s agitation and strong execution, while others worry regulatory delays or standard reviews could still weigh on that outlook, so you should expect that views on the new Auvelity decision may shift these projections in very different ways.

Explore 8 other fair value estimates on Axsome Therapeutics - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Axsome Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.